The RAS/MAPK pathway is frequently deregulated in many cancer types, including neuroblastoma, due to activating mutations in ALK/RAS/RAF or inhibitory NF1 mutations or deletions [8,85,86,87]. This evidence concerns the gene ALK and neuroblastoma.